Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for prevention and treatment of hyperuricemia in pediatric NHL and acute leukemia
2021-003176-14Phase 4
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rasburicase in hyperuricemia, non-Hodgkin lymphoma (NHL) and Acute Leukaemia, sponsored by Sanofi. Primary endpoint: Incidence of adverse events and serious adverse events.
02
Drugs
rasburicase
03
Conditions
hyperuricemianon-Hodgkin lymphoma (NHL)Acute Leukaemia
Beyond the preview
Go deeper on 2021-003176-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003176-14.